Literature DB >> 28429890

Prevalence of the reversed halo sign in neutropenic patients compared with non-neutropenic patients: Data from a single-centre study involving 27 patients with pulmonary mucormycosis (2003-2016).

Jessie Bourcier1, Pierre-Marie Heudes2, Florent Morio3,4, Thomas Gastinne1, Patrice Chevallier1, Fanny Rialland-Battisti5, Claire Garandeau6, Isabelle Danner-Boucher7, Patrice Le Pape3,4, Eric Frampas2, Philippe Moreau1, Claire Defrance2, Pierre Peterlin1.   

Abstract

Pulmonary mucormycosis (PM) is a life-threatening infection and the diagnosis can be challenging. The objective was to retrospectively explore the value of the RHS in our cohort of 27 patients with mucormycosis and its relation to neutropenia. This was a retrospective study including all patients with a diagnosis of probable or proven invasive PM according to the 2008 EORTC/MSG criteria between September 2003 to April 2016. Fisher's exact test and Mann-Whitney test, with a P-value statistically significant under .05 (P<.05), were used to compare neutropenic and non-neutropenic groups. 27 patients were eligible. The RHS could be identified in 78% of cases in the neutropenic group, and was less common in the non-neutropenic group (31%) (P<.05). Reticulations inside ground-glass opacity in case of RHS were present in 13 out of 15 patients (87%). Mucorales DNA detection by PCR on serum provided, a median time to the first PCR-positive sample of 3 days (-33 to +60 days) before diagnosis was confirmed. Six patients had IPA co-infection. In conclusion, RHS is more frequent in case of PM in neutropenic patients compare to non-neutropenic patients. Its presence in immunocompromised patients should be sufficient to promptly start Mucorales-active antifungal treatment, while its absence especially in non-neutropenic cases should not be sufficient to exclude the diagnosis.
© 2017 Blackwell Verlag GmbH.

Entities:  

Keywords:  zzm321990PCRzzm321990; neutropenic; non-neutropenic; pulmonary mucormycosis; reversed halo sign

Mesh:

Year:  2017        PMID: 28429890     DOI: 10.1111/myc.12624

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  7 in total

1.  Quantitative PCR (qPCR) Detection of Mucorales DNA in Bronchoalveolar Lavage Fluid To Diagnose Pulmonary Mucormycosis.

Authors:  Emeline Scherer; Xavier Iriart; Anne Pauline Bellanger; Damien Dupont; Juliette Guitard; Frederic Gabriel; Sophie Cassaing; Eléna Charpentier; Sarah Guenounou; Murielle Cornet; Françoise Botterel; Steffi Rocchi; Ana Berceanu; Laurence Millon
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

2.  Clinical features of pulmonary mucormycosis in patients with different immune status.

Authors:  Min Peng; Hua Meng; Yinghao Sun; Yu Xiao; Hong Zhang; Ke Lv; Baiqiang Cai
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

3.  Pulmonary Mucormycosis in Chronic Lymphocytic Leukemia and Neutropenia.

Authors:  Izza Mir; Sijan Basnet; David Ellsworth; Elan Mohanty
Journal:  Case Rep Infect Dis       Date:  2018-02-19

Review 4.  Mucormycosis of the Central Nervous System.

Authors:  Amanda Chikley; Ronen Ben-Ami; Dimitrios P Kontoyiannis
Journal:  J Fungi (Basel)       Date:  2019-07-08

5.  Radiological spectrum of invasive mucormycosis in COVID-19.

Authors:  Nandini Passi; Anshu C Wadhwa; Swati Naik
Journal:  BJR Case Rep       Date:  2022-03-09

6.  COVID-19-associated facial cutaneous mucormycosis superinfection: A potentially life-threatening disease.

Authors:  Zahra Zareshahrabadi; Amir Emami; Keyvan Pakshir; Amir Roudgari; Behzad Ghaffari; Tahere Rezaei; Golsa Shekarkhar; Kamiar Zomorodian
Journal:  Clin Case Rep       Date:  2022-07-22

Review 7.  Recent advances in the understanding and management of mucormycosis.

Authors:  Benoit Pilmis; Alexandre Alanio; Olivier Lortholary; Fanny Lanternier
Journal:  F1000Res       Date:  2018-09-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.